Svetlana Dey
About Svetlana Dey
Svetlana Dey (age 53) is a co‑founder of Bluejay Diagnostics and has served as a director since 2015. She holds a Master’s Degree in Mathematics from the State University of Mari El Republic, Russia, and brings 15+ years of healthcare consulting experience, alongside leadership roles at LMBRI and Laminar Pharma, Inc. .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bluejay Diagnostics, Inc. | Co‑founder; Director | 2015–present | Board member; no committee assignments |
| Lana Management & Business Research International, LLC (LMBRI) | President & CEO; Co‑founder | 2008–present | Led product launch/marketing consulting in US, Japan, India |
| Healthcare consulting firms | Consulting/management roles | Prior to 2008; 15+ years | Operations, product development, sales/marketing, general management |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Laminar Pharma, Inc. (US subsidiary) | Director | Current | Subsidiary of Spain‑based Laminar Pharma; focus on cancer therapy |
Board Governance
- Independence: Not deemed independent under Nasdaq rules; Board determined Wurth, Chase, Zeidman, Gemignani are independent (S. Dey is not listed) .
- Committee assignments and chair roles: None (not a member of Audit, Compensation, or Nominating & Governance; no chair roles) .
- Attendance and engagement: Board held 11 meetings in 2024 and took action 3 times by unanimous written consent; each incumbent director attended at least 75% of Board and applicable committee meetings; all directors attended the 2024 annual meeting .
- Current board slate: Nominated for re‑election at the 2025 annual meeting .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (2024) | $50,000 | Non‑employee director compensation policy; no equity granted in 2024 |
| Committee fees | $0 | Not on any committee |
| Other compensation/perquisites | Not valued (below reporting threshold) | Office space; Laminar Pharma, Inc. use of company address without payment (below reporting threshold) |
Performance Compensation
| Metric/Instrument | Grant details | Vesting/Performance Conditions | 2024 Grants |
|---|---|---|---|
| Equity awards (RSUs/PSUs) | None disclosed for directors | N/A | None |
| Options | None granted in 2024 | N/A | None |
| Performance cash bonus | Not applicable for directors (policy provides cash retainers) | N/A | None |
The company noted limited capacity under equity incentive plans and focus on cash compensation given sustained stock price declines; this context applied to executives but helps explain no director equity awards in 2024 .
Other Directorships & Interlocks
| Entity | Type | Role | Potential Interlock/Notes |
|---|---|---|---|
| Laminar Pharma, Inc. (US) | Private subsidiary | Director | Company permits Laminar Pharma, Inc. to use Bluejay’s main facility as its registered business address without payment (below reporting threshold) |
| LMBRI | Private consulting | President & CEO; Co‑founder | Co‑owned with CEO Neil Dey; holds Bluejay shares via LMBRI |
Expertise & Qualifications
- Co‑founded Bluejay Diagnostics with experience spanning healthcare product development, sales and marketing, and general management .
- Senior leadership and operating expertise: President & CEO of LMBRI since 2008 .
- Technical/industry focus: Involved in operations and management of healthcare and life sciences product development .
- Education: Master’s Degree in Mathematics (State University of Mari El Republic, Russia) .
Equity Ownership
| Component | Quantity/Detail | Terms/Strike | % of Outstanding |
|---|---|---|---|
| Shares held directly | 6 shares | N/A | <1% |
| Indirect ownership via LMBRI | 511 shares (shared voting/dispositive power) | N/A | <1% |
| Options included in beneficial ownership | 3 shares underlying options | $22,320.00 per share | <1% |
| Total beneficial ownership | 520 shares | Various | <1% (based on 1,494,167 shares outstanding as of May 2, 2025) |
| Pledging/Hedging policy | Pledging and hedging prohibited by insider trading policy | Policy applies to directors | N/A |
Board Governance
| Attribute | Status/Detail |
|---|---|
| Independence | Not independent (spouse of CEO; not listed as independent) |
| Committee memberships | None |
| Attendance | ≥75% of Board/committee meetings in 2024; attended 2024 annual meeting |
| Years of service | Director since 2015 |
Governance Assessment
- Independence risk and potential conflicts: Ms. Dey is married to CEO Neil Dey; she and Mr. Dey co‑own LMBRI and both serve as officers/directors of Laminar Pharma, Inc., which uses Bluejay’s address without payment (below reporting threshold). These relationships create related‑party exposure and undermined independence classification under Nasdaq rules .
- Committee influence: Not serving on audit, compensation, or nom/gov committees reduces formal oversight leverage; mitigates direct committee‑level conflict risk but limits board effectiveness contributions in key governance areas .
- Attendance and engagement: Met minimum engagement threshold (≥75% attendance) and attended the annual meeting, indicating baseline participation .
- Ownership alignment: Beneficial ownership is de minimis (<1%), and no director equity grants in 2024; alignment relies more on policy protections (anti‑hedging/pledging) than material skin‑in‑the‑game exposure .
- RED FLAGS:
- Spousal relationship with CEO (structural conflict) .
- Related‑party exposure via LMBRI and Laminar Pharma, Inc. using company facilities without payment (even if below reporting threshold) .
- No committee membership (limited governance oversight footprint) .
- Offsetting controls: Anti‑hedging and anti‑pledging policies apply to directors, reducing misalignment risk from derivatives or collateral pledges .
Overall signal for investors: Governance independence concerns and related‑party proximity are the primary issues; limited committee roles reduce direct influence on compensation, audit, and nomination matters, while policy‑level protections and baseline attendance partially mitigate confidence risk .